source
- AbbVie bets up to $1.47B for Nxera’s discarded IBD programAbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.BioSpace · 4d ago↗ source
- Servier’s $1.55 billion Becker muscular dystrophy drug fails pivotal Phase 3 trialServier announced that its experimental drug for Becker muscular dystrophy did not meet its primary endpoint in a Phase 3 trial called GRAND CANYON. The drug, sevasemten, was acquired from Edgewis…